Autolus Therapeutics (AUTL)
(Delayed Data from NSDQ)
$4.00 USD
-0.08 (-1.96%)
Updated Apr 26, 2024 04:00 PM ET
After-Market: $4.00 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
F Value D Growth A Momentum D VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
AUTL 4.00 -0.08(-1.96%)
Will AUTL be a Portfolio Killer in April?
Zacks Investment Research is releasing its prediction for AUTL based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for AUTL
Are Medical Stocks Lagging Ascendis Pharma (ASND) This Year?
Strength Seen in Autolus Therapeutics PLC Sponsored ADR (AUTL): Can Its 6.3% Jump Turn into More Strength?
AUTL: What are Zacks experts saying now?
Zacks Private Portfolio Services
2seventy bio, Inc. (TSVT) Surges 28.2%: Is This an Indication of Further Gains?
Autolus (AUTL) Selects Cardinal Health for Cell Therapy Supply
Has Acasti Pharma (ACST) Outpaced Other Medical Stocks This Year?
Other News for AUTL
Amgen’s Blincyto data send Cullinan higher
These Are The Biotechs Showing Up At The Biggest Cancer Meeting Of The Year (Oral Presentations)
AUTL Makes Notable Cross Below Critical Moving Average
Abstract for longer-term follow-up and additional data analysis of Pivotal Phase 2 FELIX study of obe-cel for adult r/r B-ALL selected for an oral presentation at ASCO
Autolus Therapeutics to Report First Quarter 2024 Financial Results and Host Conference Call on May 14, 2024